medigraphic.com
ISSN 1561-3186 (Electronic)

2011, Number 1

<< Back Next >>

Rev Acta Médica 2011; 13 (1)

Use of antimicrobial agents in sepsis control of burnt patient

Miquet RLM, Rodríguez GR

Language: Spanish
References: 51
Page: 89-100
PDF size: 145.91 Kb.


ABSTRACT

Sepsis remains a threat for the course of patient presenting with extensive burns given its immunosuppression condition. Many factors are identified favoring the development and microbial growth; nowadays there are changes in the flora prevalent in the unit of the «Hermanos Ameijeiras» Clinical Surgical Hospital characterized by antimicrobial resistance and more aggressive behavior. The objective of present paper is to make a review of the distinctive features of the disease due to burns placing patient in conditions favorable to develop infection and/or sepsis identified as high consumers of antimicrobials, however, morbidity and mortality due a septic cause is high. We conclude that the better therapy is that aimed to prevention of infection and sepsis.


REFERENCES

  1. Borges H, García R. Atención al paciente quemado en unidades especializadas. En: Borges H, García R, González G: Manual de procedimientos de diagnóstico y yratamiento en caumatología y cirugía plástica. Ed. Pueblo y Educación. Ciudad de La Habana: Editorial Pueblo y Educación 1984; p. 25- 48.

  2. Shaffle JR, Davis B, William P. Recent outcomes in the treatment of burn injury in the United Status: a report from the American Burn Association patient registry. J Burn Care Rehabil. 1995;16:216-32.

  3. Latenser BA, Miller SF, Bessey PQ, Browning SM, Caruso DM, Gomez M, et al. National Burn Repository 2006: a ten-year review. J Burn Care Res. Sep- Oct 2007;28(5):635-58. [Medline].

  4. Anuario estadístico nacional de Cuba. Estadísticas de salud en cuba. Mortalidad. Bibloteca virtual de salud disponible en URL: http://bvs.sld.cu/cgi-bin/wxis/anuario

  5. Registro de ingresos. Departamento de estadísticas. Hospital Hermanos Ameijeiras.

  6. Cuenca J, Pérez C, Aguirre A, Schiattino I, Aguillón JC. Genetic polymorphism at position -308 in the promoter region of the tumor necrosis factor (TNF): Implications of its allelic distribution on susceptibility or resistance to diseases in the Chilean population. Biol Research 2001; 34: 237-41.

  7. Rosmond R, Chagnon M, Bouchard C, Bjorntorp P. G- 308A Polymorphism of the tumor necrosis factor ? gene promoter and salivary cortisol secretion. J Clin Endocrinol Metab 2001; 86: 2178-80.

  8. Saldaña S L , Pancorro M J , Matos S R, Lanchipa A P Y, Regis R A. Insuficiencia cutánea aguda Dermatol. peru. 2002; 12: 175-182.

  9. Rangel G. Infección en quemaduras Cir Plast 2005; 15:111-7.

  10. Cuenca-Pardo J: Fase inflamatoria en el paciente quemado Cir Plast 2001;11:90-7.

  11. Ong YS, Samuel M, Song C. Meta-analysis of early excision of burns. Burns. 2006;32:145-50. [Medline].

  12. Rangel HG. Infección en quemaduras Cir Plast 2005;15:111-7

  13. Pruitt, Basil A., Burn wound infections: Current status, World J Sur 1998;22

  14. Peck, M., Surveillance of burn wound infections: A proposal for definitions. Care burns Rehabilit. 1998;19:386

  15. Cerdá Cerdá E. Descontaminación digestiva selectiva Rev. Electrónica Med Intensiva. 2004: 4.

  16. Rodriguez Garcell R, Miquet Romero LM, Estudio de la sepsis en pacientes quemados. Rev. electrónica Portales Médicos. Disponible en: (http://www.portalesmedicos. com) 2008;3:21

  17. Murray C, Hospenthal R.D, Burn wound infections disponible en: (http://www.medscape.com/public/ copyright), 2008.

  18. Albrecht MC, Griffith ME, Murray CK, Chung KK, Horvath EE, Ward JA, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg. 2006;203:546-50. [Medline].

  19. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006;19:403- 34. [Medline].

  20. Regules JA, Carlson MD, Wolf SE, Murray CK. Analysis of anaerobic blood cultures in burned patients. Burns. 2007;33:561-4. [Medline].

  21. Schofield CM, Murray CK, Horvath EE, Cancio LC, Kim SH, Wolf SE, et al. Correlation of culture with histopathology in fungal burn wound colonization and infection. Burns.2007;33:341-6. [Medline].

  22. Covarrubias P, Broussain P, Weibel A, Caprile I, Correa C, Silva S: Infección por Virus Herpes Simple en el paciente pediátrico quemado: reporte de 2 casos y revisión bibliográfica; Rev. Ped. Elec. [en línea] 2005: 2:18 – 23.

  23. León Rodríguez Y. Caracterización de la sepsis en la unidad de quemados del Hospital Hermanos Ameijeiras. Período 2006 – 2008. Tesis para optar por el Título de Master en Enfermedades Infecciosas. Facultad Calixto García. Ciudad de La Habana 2009.

  24. Miquet Romero LM, Rodríguez Garcell R, Pinilla Mikan SL. Necrectomía quirúrgica precoz en el tratamiento del paciente quemado. Rev Electrón Portales Medicos. 2008; 3:7 disponible en (http://www.portalesmedicos.com)

  25. Hernández Collado MC. Infección local en la unidad de quemados. Rev Electrónica Portales Medicos.com. 2009;6:10 disponible en (http://www.portalesmedicos. com)

  26. Álvarez FL. Decálogo de normas para la utilización de antibióticos en pacientes críticos. Med.Int. 2000;24:69- 77

  27. Dacso CC, Luterman A, Curren W. Tratamiento antibiótico sistémico en pacientes quemados. Clín Quirurg de Norteam.1987: 63-71.

  28. Mena Miranda VR, Díaz Calderón Y. Desescalado antimicrobiano: nueva opción para el manejo de la sepsis grave en la unidad de cuidados intensivos pediátricos Rev Cubana Med Inten Emerg 2008;7

  29. Beltrán C B. Farmacocinética y farmacodinamia de antimicrobianos: Utilidad práctica. Rev Chil Infect 2004; 21 (Supl 1): S39-S44.

  30. Boucher BA, Kuhl DA, Hickerson WL. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992;14:458-63.

  31. Dacso CC, Luterman A, Curreri PW. Systemic antibiotic treatment in burned patients. Surg Clin North Am 1987;67:57-68.

  32. Rebuck J, Fish D, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 2002; 22: 1216-25.

  33. Díaz de León PM, Brines GC, Gil RN, Mendoza TA Insuficiencia renal aguda (IRA) en el paciente quemado Rev Asoc Mex Med Crit Ter Int 2002; 16: 136-44

  34. Onyeji C, Nicolau D, Nightingale C, Quintiliani R. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections. Antimicrob Agents Chemother 1994; 38: 1112-17.

  35. Amin K, Kauffman CA. Fever of unknown orignin. Am Fam Physician 2003; 68:2223-8.

  36. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2002; 2:171-9

  37. Nitsche D, Schulze C, Oesser S. Impact of different classes antimicrobial agents on plasma endotoxin activity. Arch Surg 1996; 131:192-9

  38. Van den Berg C, Neeling de AJ, Schot CS. Delayed antibiotic-induced lysis of Escherichia coli in vitro is correlated with enhancement of LPS release. Scand J Infect Dis; 1992;24: 619-27

  39. Cohen J, McConnell JS. Release of endotoxin from bacteria exposed to ciprofloxacin and its prevention with polymyxin B. Eur J Clin Microbiol 1986; 5:13-7

  40. Bingen E, Goury V, Bennani H et al. Bactericidal activity of beta-lactams and amikacin against Haemophilus influenzae: effect on endotoxin release. J Antimicrob Chemother 1992; 30:165-72

  41. Crosby HA, Bion JF, Penn CW et al. Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol 1994; 40:23-30

  42. Prins JM, Kuijper EJ, Mevissen ML. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995; 63:2236-42

  43. Narita K, Koide N, Morikawa A. Differential release of endotoxin from Pseudomonas aeruginosa treated with betalactam antibiotics and its effect on the lethal activity. Jpn J Med Sci Biol 1997; 50:233-9

  44. Wang S, Wu B, Huang F. An experimental study of antibiotic – induced endotoxin release in Pseudomonas aeruginosa bacteremia inburned rats. Zhonghua Shao Shang Za Zhi 2000; 16:93-5.

  45. Wang HM, Cao WF, Peng YZ et al. Changes in plasma levels of LPS, TNFalpha and IL-6 in burn patients with severe infection treated with imipenem or cefoperazone. Zhonghua Shao Shang Za Zhi 2004;20:95-7.

  46. Mock CN, Jurkovich GJ, Dries DJ et al. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg 1995; 130:1234-40.

  47. Silvestre Pérez M A., Jaén Matoses MS, Peiró Tudela MC, López Navarro AM, Braulio JT. Anestesia y reanimación del gran quemado pediátrico Rev. Esp Anestesiol Reanim 2004; 51: 253-67

  48. Ocaña PM. Interacciones fármaco-nutrientes en nutrición parenteral: En Arenas MH, Anaya PR, editores. Nutrición enteral y parenteral, ed Mexico: McGraw-Hill interamericana ed; 2007. p. 163-73.

  49. Monafo, William W., Topical Therapy For Burns, Surg Clin North Am, 1987;67: (1)

  50. Dalley J.A, Lipman J, Dean R, Venkatesh B, Rudd M, Roberts, SM, Cross E.S. Tissue Accumulation of Cephalithin in Burns: a comparative study by microdialysis of subcutaneous interstitial fluid Cephalithin concentrations in burn patients and healthy volunteers. Antimicrobial Agents and Chemotherapy 2009; 53 (1): 210-15.

  51. Sampol E, Jacquet A, Viggiano M, Bernini V, Manelli JC, Lacarelle B and Durand A. Plasma, urine and skin pharmacokinetics of cefepime in burns patients. Journal of Antimicrobial Chemotherapy 2000; 46, 315-17.




2020     |     www.medigraphic.com